Online Launch of "Expert Consensus on the Use of Contezolid in the Treatment of Tuberculosis" Provides New Strategies for Drug-Resistant Tuberculosis Treatment

December 18, 2024, the Expert Consensus on the Use of Contezolid in the Treatment of Tuberculosis was officially launched online on the China National Knowledge Infrastructure (CNKI) platform, published in the Chinese Journal of Antituberculosis (Certificate No.: 202412189916). This landmark consensus from Chinese experts in the field of tuberculosis not only provides new treatment strategies and scientific evidence for the clinical management of tuberculosis but also marks a new phase in the application of Contezolid in tuberculosis treatment. It injects new vitality into the global tuberculosis prevention and control efforts.
Tuberculosis remains one of the most significant public health threats worldwide, with treatment success rates still at a relatively low level[1]. In this context, oxazolidinone drugs are playing an increasingly important role in the treatment of drug-resistant tuberculosis (DR-TB) and in the development of new drugs and treatment regimens. As a new generation of oxazolidinone drugs, Contezolid has seen continuous clinical exploration and scientific research in tuberculosis treatment since its launch. Clinical physicians have expressed an increasing demand for guidelines or standards regarding its clinical application.
To standardize and guide healthcare professionals in the use of Contezolid for tuberculosis treatment, addressing issues such as indications, dosage, and duration that are not adequately covered in the drug’s labeling or existing tuberculosis treatment guidelines, the Editorial Committee of the Chinese Journal of Antituberculosis and the Chinese Antituberculosis Association organized a nationwide expert discussion. They have developed the Expert Consensus on the Use of Contezolid in the Treatment of Tuberculosis. It is hoped that this consensus will provide valuable guidance to domestic clinicians and help promote the rational use of Contezolid in clinical practice.
Notably, this consensus recommends Contezolid as part of combination therapy for adult tuberculosis, especially in cases of drug-resistant tuberculosis (MDR/RR-TB, pre-extensively drug-resistant TB, and extensively drug-resistant TB), particularly for patients who are intolerant to drugs due to side effects such as bone marrow suppression and neuropathy, or for those who cannot continue linezolid therapy due to adverse reactions.
The publication of the Expert Consensus on the Use of Contezolid in the Treatment of Tuberculosis not only further affirms the potential of Contezolid in anti-tuberculosis treatment but also provides scientifically-based guidance for its clinical application. This consensus will strongly promote the use of Contezolid in tuberculosis treatment, offering hope for more patients. As more clinical data is accumulated and research progresses, the future of Contezolid’s application is expected to expand further, contributing significantly to global health.
About Contezolid
Contezolid tablets (brand name: Youxitai®) are a new generation of oxazolidinone antibiotics independently designed and developed by Shanghai MicuRx Pharmaceutical Co., Ltd. (Stock Code: 688373.SH). They are used to treat infections caused by multi-drug-resistant Gram-positive bacteria. Contezolid was approved by the National Medical Products Administration (NMPA) under a priority review and approval procedure on June 1, 2021, and was included in the 2021 National Medical Insurance Catalogue (Category B) in December of the same year. In 2023, Contezolid tablets successfully passed the National Medical Insurance review and renewal process, securing their place in the 2023 National Medical Insurance Catalogue.
At the same time, the company is advancing the clinical trials of the Contezolid prodrug injection form (MRX-4). MRX-4 is converted into Contezolid in the body to exert its therapeutic effect, greatly expanding clinical usage scenarios. Once approved, it is expected to provide more convenient medication options for critically ill patients and those who are unsuitable for oral administration.
References:

1. Wenjuan Nie, Naihui Chu. Expert Consensus on the Use of Contezolid in the Treatment of Tuberculosis [J/OL]. Chinese Journal of Antituberculosis, 1-12 [2024-12-23]. https://doi.org/10.19982/j.issn.1000-6621.20240480.